Gistafen Sequifenadine 20 tablets 50mg

$38.00

Gistafen Sequifenadine 20 tablets 50mg

Acute and chronic allergic diseases treatment

Free international shipping

Description

Gistafen Sequifenadine 20 tablets 50mg

 

Pharmacological group: Antihistamines for systemic use. ATX code R06A X32.

Composition:Active ingredient: Sequifenadine

1 tablet contains sequifenadine hydrochloride in terms of anhydrous substance 50 mg; excipients: lactose monohydrate, microcrystalline cellulose, corn starch, colloidal silicon dioxide, magnesium stearate.

Indications:Acute and chronic allergic diseases: hay fever, allergic rhinitis, rhinosinusopathy (atopic and infectious-allergic) allergic reactions associated with the use of medicines, food products, household chemicals.

Allergic and non-allergic diseases accompanied by itching (allergic or atopic dermatitis, skin vasculitis, neurodermatitis, lichen planus) in adults. Atopic and infectious-allergic dermatitis in children over 12 years of age.

Prevention of allergic diseases (during seasonal exacerbation) and maintenance therapy in adults.

Contraindications:Hypersensitivity to sechifenadine or to excipients of the drug, attacks of bronchial asthma.

Method of administration and dosage:Take  orally, after meals, with water.

Adults: Acute chronic allergic diseases: 50-100 mg 2-3 times a day. Allergic and non-allergic diseases accompanied by itchy skin: 50-100 mg 2-3 times a day. Usually the therapeutic effect occurs 3 days after treatment.

The duration of treatment is 5-15 days. If necessary, repeat the treatment. Prevention of allergic diseases (before seasonal exacerbation) and maintenance therapy: 50 mg 2 times a day. For prevention, it is recommended to start taking the drug 2 weeks before the expected allergic reaction. If you miss one or more doses of the drug, continue treatment in previously prescribed doses.

Children from 12 years old: Atopic and infectious-allergic dermatitis: 50 mg 3 times a day. The course of treatment is 7 days.

Pharmacodynamics: The drug is an H1 receptor blocker as well as a moderate 5HT1 serotonin receptor blocker, thus attenuating the action of histamine and serotonin allergy mediators. A feature of the drug is that it makes an antihistamine effect not only by blocking H1 receptors, but also by reducing the content of histamine in tissues by accelerating its metabolism by the enzyme diamine oxidase, which breaks down endogenous histamine.

Sekhifenadine prevents or weakens the spasmogenic effect of histamine and serotonin on the smooth muscles of the bronchi, intestines, blood vessels, reduces capillary permeability, and has a pronounced antiallergic effect. Sekhifenadine affects the immunological reactivity of the body, reducing the number of antibody-forming and rosette-forming cells in the spleen, bone marrow, lymph nodes, and also reduces the increased concentration of class A and G immunoglobulins.

The drug poorly penetrates the blood-brain barrier, which explains the absence of a pronounced inhibitory effect on the central nervous system, however, in some cases, with individual hypersensitivity to the drug, a slight sedative effect may be noted. Sekhifenadine does not affect the biochemical parameters of blood and urine (including the concentration of glucose and cholesterol in the blood), the level of blood pressure, electrocardiogram indicators, does not increase the latent period of the conditioned reflex and does not affect the electroencephalogram indicators.

Application features: You should be careful in patients with impaired renal function (start treatment with a minimum dose), with severe diseases of the cardiovascular system, digestive tract, and liver. There are no data from clinical studies on the use of the drug in the elderly. The drug contains lactose, therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use the drug. During the period of treatment, one should refrain from drinking alcohol.

The ability to influence the reaction rate when driving or operating machinery:Persons whose work requires a quick physical and mental reaction (transport drivers) should first be established (by short-term intake) that the drug does not have a hypnotic effect on them. With a sedative effect, refrain from driving.
Use during pregnancy or lactation: The safety of use in pregnant women has not been established, therefore the drug is contraindicated during this period. During breastfeeding, the use of antihistamines is not recommended due to the possibility of negative effects on the central nervous system of the child. If necessary, use of the drug should stop breastfeeding.
Overdose: The drug is low-toxic. Symptoms: dry mucous membranes, headache, vomiting, abdominal pain and other dyspeptic symptoms. Treatment: symptomatic therapy. No specific antidote known.
Shelf life:

4 years.

Storage conditions:
Store in its original packaging at a temperature not exceeding 25 °C.

Produced in Latvia